explore -WSS

explore

author：leisure time 2025-09-28 22:53:41 - browse：275

Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill. -- health policy coverage from STAT — Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill in 2021. Susan Walsh/AP

WASHINGTON — One of the top health care committees in the Senate is assembling ideas for bipartisan legislation to address drug shortages, three Senate aides and three lobbyists told STAT.

The talks, led by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) are in the early days, but they could move the debate over drug shortage reforms into a new phase. The committee has jurisdiction over Medicare and Medicaid payment policies for hospitals. Other committees that have tried tackling the issue have jurisdiction mostly over the Food and Drug Administration.

The panel is tentatively aiming to hold a hearing on the issue in November, the sources said. The panel has also started accepting input from outside stakeholders, one lobbyist said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Readers respond to H5N1 and livestock movements, and more

explore

WSS

Abridge raises $150m as clinical notes automation market heats up

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Data integrity in scientific journals requires "effort" by publishers, institutions

Surprise medical billing ban raises prices elsewhere

As AI regulations shape up, health tech startups beg for clarity

Medicare Advantage enrollment hits roughly 33.4 million

knowledge

explore

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

HIV vaccine remains elusive. Immunologists keep trying new ideas

Anesthesiologist group: stop taking Ozempic before surgery

In 'major milestone,' FDA approves first cell therapy for solid tumors

23andMe had bad news about my health. I wish a person had delivered it

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

What does generative AI mean for health care? We asked experts

Bird flu: Don't repeat Covid's 'health versus the economy' framing

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

leisure time

Criminal prosecution for violating HIPAA: an emerging threat

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Weight loss drugs aren’t covered by Obamacare. That may change

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Ukraine seeks to reclaim its role as a hub for clinical trials

Researchers tackle phage therapy hurdles for wider adoption

hotspot

focus

explore

hotspot